Background Enhanced influenza vaccines may improve protection for older adults, but
comparative immunogenicity data are limited. Our objective was to examine immune …

Background A number of enhanced influenza vaccines have been developed for use in
older adults, including high-dose, MF59-adjuvanted, and intradermal vaccines. Methods We …

Introduction Older adults are prioritized for influenza vaccination but also have lowered
antibody responses to the vaccine. Higher-doses of influenza antigen may increase immune …

Background Influenza-associated morbidity and mortality has not decreased in the last
decade, despite increased receipt of vaccine. To improve the immunogenicity of influenza …

Background Studies among individuals ages≥ 65 years have found a moderately higher
relative vaccine effectiveness (RVE) for the high-dose (HD) influenza vaccine compared with …

BACKGROUND: High-dose trivalent influenza vaccine was developed to improve antibody
responses to influenza vaccine in the elderly and hence potentially impact favorably on …

Background As compared with a standard-dose vaccine, a high-dose, trivalent, inactivated
influenza vaccine (IIV3-HD) improves antibody responses to influenza among adults 65 …

Background Improved influenza vaccines are needed to control seasonal epidemics. This
trial compared the protective efficacy in older adults of a quadrivalent, recombinant influenza …

Background A randomized trial demonstrated that a high-dose inactivated influenza vaccine
(IIV-HD) was 24.2% more efficacious than a standard-dose vaccine (IIV-SD) against …

We conducted a randomized, controlled, multicenter, phase II study to evaluate the
immunogenicity and safety of an investigational intradermal (ID) trivalent influenza vaccine …